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This study is part of a larger project that examines the safety and clinical effectiveness, acceptability 
and cost effectiveness of flexible delivery of natalizumab by ambulatory care nurses for people with 
multiple sclerosis. Currently, people with multiple sclerosis receive natalizumab intravenous infusions 
through an outpatient intravenous therapy service. Using a hospital in the home model to offer people 
with multiple sclerosis natalizumab infusions in their own home could be an improved model of care 
for patients. However, no previous qualitative research has focused on healthcare workers’ and 
patients’ experiences of a change in the model of care from outpatients to the home for the infusion of 
natalizumab. This Masters by Research is by publication and includes two published studies as follows. 
 
The first stage of this study aimed to understand the experiences of people with multiple sclerosis who 
received infusions of natalizumab at home instead of in hospital. Returning every four weeks to an 
outpatient department to complete an intravenous infusion can be taxing for patients with chronic 
disease. This exploratory-descriptive study incorporated face-to-face digital-recorded interviews with 
people with multiple sclerosis. Twelve people with multiple sclerosis (two males and 10 females) aged 
between 18 and 56 years participated in this study. A major theme that emerged from the findings was 
the importance of ‘patient-centredness’, or the positive contribution of having patients at the centre of 
care when delivering home infusions. This encompassed three subthemes: ‘in the comfort of their own 
home’, ‘convenience for patients and their families’ and ‘saving time and money’. Patient-centred care 
was an important part of the model of care because it provided flexibility for the participants in 
managing their home and work–life commitments. Although home infusion therapy requires a team 
approach, this study found that delivering patient-centred home infusions provided significant 
satisfaction for people with multiple sclerosis.  
 
The second stage of this study explored healthcare workers’ experiences of delivering natalizumab 
infusions in a home environment. In this exploratory-descriptive inquiry, the researcher sought to gain 
an understanding of healthcare workers’ perspectives on the patient-centred model of care of home 
infusions of natalizumab. There were 12 participants from two main groups of healthcare workers who 
participated in delivering natalizumab infusions during the six-month study period. Four participants 
were from a private provider of home nursing care and eight were from a tertiary hospital ambulatory 
v 
care day unit. Thematic analysis of the data identified three overarching themes: ‘preparing for 
change’, ‘focussing on the patient’, and ‘professional support’. 
 
Healthcare workers’ practice experience is an important component of patient-centred care during the 
delivery of an infusion at a patient’s home and flexible processes are required to deliver quality home 
care. Flexibility, communicating clearly and being willing to work in a team, especially between the 
hospital and the home nursing staff, were important factors in the safe delivery of infusions at home. 
Managing the logistics of delivering a flexible and safe home therapy service, though time consuming, 
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Home care service is used in this thesis to refer to infusion therapy that is provided in the home 
(Alexander et al. 2011). 
 
Models of care ‘broadly defines the way health services are delivered’ (Agency for Clinical 
Innovation 2013, p. 3). 
 
Multiple sclerosis is defined as ‘an autoimmune disease of the central nervous system that 
results in demyelination and axonal degeneration’ (Miller, Karpinski & Jezewski 2012, p. 39). 
 
Outpatient intravenous therapy service is used to refer to infusion therapy that is provided 
without an overnight stay in a hospital (Alexander et al. 2011). 
 
TYSABRI® (natalizumab) ‘is a prescription medicine used to treat adults with relapsing forms 
of multiple sclerosis to slow the worsening of symptoms common in people with multiple 
sclerosis and to decrease the number of flare-ups (relapses)’ (Biogen 2016). 
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Chapter One: Introduction 
Introduction 
For people with chronic disease, returning on a monthly basis to an outpatient department to complete 
an intravenous infusion can be very taxing. Over the last century, the healthcare system has 
experienced a major change in the location of delivery of infusion for people with chronic disease 
(Beijer et al. 2008). For instance, oncology patients are no longer required to be admitted to hospital 
for the infusion of chemotherapy drugs. They now have alternative infusion settings, either in a health 
service oncology clinic, outpatient intravenous therapy service, or a community setting. Chataway et 
al. (2006) noted that when considering how to improve the delivery of care there should be an emphasis 
on minimising or avoiding outpatient hospital care for people with chronic disease who receive 
intravenous therapy. These improvements aim to reduce the risk of hospital-acquired infections and 
increase the quality of life for people with chronic disease. Multiple sclerosis (MS) is one chronic 
disease that requires regular ongoing treatment. This requires access to health services for 
administration of the treatment. The regular travel and time commitment for hospital treatment may 
impact on the person’s quality of life. People with MS can be treated in an outpatient intravenous 
therapy service (OITS), but the community/home environment may be a better option to fit in with 
their personal and work routines. This thesis by publication will explore this issue in more depth. 
Multiple sclerosis 
Multiple sclerosis (MS) was first described by clinicians at the end of the nineteenth century 
(Compston & Coles 2002). It is an inflammatory chronic disease that affects the central nervous 
system, which includes the optic nerves, spinal cord and brain, with an unknown cause. People with 
MS can present with a complex range of neurological symptoms. Some of the major indicators include, 
but are not limited to, fatigue, heat intolerance, walking difficulties, visual disorders, gastrointestinal 
disturbance and muscle weakness. People with MS may have a mix of symptoms that can negatively 
impact their quality of life (Koopman, Benbow & Vandervoort 2006; McCormack 2013; Levin 2007). 
Generally, this special condition or disease may cause impairment and disturbance in many areas of 
an individual’s life including work, activities of daily living and family functions. Each and every day 
poses unique challenges, not only to the individual but also to their family members (Koopman, 
Benbow & Vandervoort 2006). Worldwide, around 2–2.5 million people have been diagnosed with 
MS and over 23,000 people in Australia, where about three quarters of these are female (Compston & 
Coles 2002; Kornek 2015; Multiple Sclerosis Society Australia 2012). 
2 
 
Multiple Sclerosis Society Australia (2012) noted that the majority of people with MS are between the 
ages of 15 to 50 years and symptoms are often first reported in young adults. The Multiple Sclerosis 
Society Australia (2012) and Levin (2007) highlighted four types of MS progression: 
 
• relapsing-remitting multiple sclerosis  
• primary-progressive multiple sclerosis  
• secondary-progressive multiple sclerosis 
• relapsing-progressive multiple sclerosis 
 
Kornek (2015) and Runmarker and Andersen (1993) stated that most people with MS start out with 
relapsing-remitting multiple sclerosis (RRMS). This is characterised by attacks, when symptoms flare 
up, or exacerbations, called ‘relapses’, followed by a brief period of time when no symptoms are 
present, called ‘remission’ (Kornek 2015; Multiple Sclerosis Society Australia 2012). A relapse is 
defined as ‘a period of at least 24 hours in which new symptoms develop, or existing ones deteriorate’ 
(Noyes et al. 2011, p. 358). In this thesis, only RRMS will be discussed.  
 
For many decades, there has been no cure for people diagnosed with MS. However, there are several 
medications known as disease-modifying therapies that are recommended to treat the disease process 
(Elovaara 2011; Gajofatto & Benedetti 2015; Goodin 2008; Kappos et al. 2004; Stuve 2009). 
Compston and Coles (2002) and Miller, Karpinski and Jezewski (2012) stated that, prior to the 1990s, 
there were no disease-modifying therapies to reduce the number and severity of relapses that occur 
with MS. Now, the US Food and Drug Administration, together with the European Medicines Agency, 
have approved 13 drugs for use as disease-modifying therapies in RRMS (Gajofatto & Benedetti 2015; 
Kornek 2015). The availability of these therapies offers the individual several years of controlling the 
disease and improving their quality of life. Gajofatto and Benedetti (2015, p. 545) emphasised that 
these therapies ‘modulate or suppress with different mechanisms the autoimmune process that 
underlies the disease’, thereby minimising the occurrence of relapse or preventing disease progression. 
Over the last few years, a wide variety of disease-modifying therapy agents have been developed for 
the treatment of people with MS, including natalizumab. Natalizumab is one of the first targeted 
disease-modifying therapies approved for the treatment of adults with RRMS (McCormack 2013; 
Nicholas et al. 2014; Stuve 2009).  
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Natalizumab therapy 
Natalizumab is a disease-modifying therapy that either slows or stops the progression of disability, 
offering effective relief of both symptomatic and neurological disability activity. Worldwide, 
natalizumab is used as a first line of treatment for people with RRMS (Kamat et al. 2009; McCormack 
2013; Nicholas et al. 2014; O’Connor & Kremenchutzky 2015; Stuve 2009; Totaro et al. 2014). It has 
a positive outcome not only in resolving the neurological symptoms but also improving the quality of 
life for many. However, natalizumab therapy recipients have the risk of developing progressive 
multifocal leukoencephalopathy (PML), which is an infectious disease caused by the John 
Cunningham virus (Ferenczy et al. 2012), which causes progressive damage or inflammation of 
leukocytes within the central nervous system (McCormack 2013; Nicholas et al. 2014; Stuve 2009). 
Gensicke et al. (2012) reported that there is a very low (1 in 1,000) risk of PML when receiving 
natalizumab therapy. Despite the chances of developing PML, natalizumab is a favourable treatment 
option for adults with highly active RRMS (McCormack 2013; Miller, Karpinski & Jezewski 2012; 
Nicholas et al. 2014). The potential benefits of decreasing the progression of disability, stabilising the 
neurological symptoms and increasing the quality of life must be weighed against the risk associated 
with PML, which is often a fatal illness.  
 
Natalizumab is sold under the brand name Tysabri (manufactured by Biogen Idec and Elan 
Pharmaceuticals) and it is now available as an infusion therapy in several countries. Tysabri was 
developed in 2004 in the United States and approved by the Food and Drug Administration for the 
treatment of RRMS. After three months on the market, Tysabri was withdrawn because of the related 
incidence of PML on people with MS (Langer-Gould et al. 2005) and people with Crohn’s disease 
(Bickston & Muniyappa 2010). It was released back onto the market in the European Union in 2006, 
after Tysabri was declared safe and well-tolerated over the long term for managing RRMS.  
 
Natalizumab is a monospecific agent, which is a humanised monoclonal antibody directed against α4- 
integrin adhesion molecules for the management of RRMS (Kamat et al. 2009; McCormack 2013; 
Stuve 2009). Clinical studies have shown that people with relapsing forms of MS who receive 
natalizumab infusions have positive outcomes from the treatment. A study by Polman et al. (2006) 
showed a decrease in relapse of up to 68% and a decrease of approximately 50% in the risk of disease 
progression compared to placebo treatment in people with MS. Recently, natalizumab therapy has 
demonstrated a beneficial effect in the treatment of MS by either inducing remission in disease activity 
or improving the quality of life. 
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Current literature and post-marketing studies to date have reported that natalizumab infusion is 
generally safe in a hospital setting. During clinical studies, although natalizumab was well-tolerated 
with a positive safety profile, less serious adverse events were well-documented (Hellwig et al. 2008; 
Polman et al. 2006; Totaro et al. 2014). The commonly reported adverse events were headache, fatigue 
and mild infection (such as urinary tract infection). Polman et al. (2006) confirmed that most of these 
adverse events were manageable and only resulted in a reduction in the infusion rate. In addition, in a 
study by Hellwig et al. (2008), it was reported that these adverse events may be prevented by 
combining a low dose of intravenous steroids and antihistamines. Healthcare professionals must 
consider the frequency of adverse events during natalizumab infusions. Moreover, Stuve and Cutter 
(2014) noted that the activity of the disease is difficult to detect in many natalizumab recipients, due 
to a need for long-term data to observe potential long-term benefits. Over the last ten years, many 
studies have documented the use of natalizumab infusion therapy in people with RRMS in OITS 
(Kamat et al. 2009; Miller, Karpinski & Jezewski 2012; Polman et al. 2006; Totaro et al. 2014; Van 
Pesch, Sindic & Fernandez 2016). 
Delivery of home care 
The treatment of infusion therapy to chronically ill patients has traditionally been delivered in an OITS 
setting and supported by clinical practice policies. However, the practice of home infusion therapy is 
a practicable alternative to OITS not only because of the cost benefits but because it keeps patients 
away from the hospital setting (Gardner et al. 2003). Internationally, home infusion treatment 
programs have been established because of the need to reduce the demand for inpatient and outpatient 
hospital services, to decrease the risk of infections and to control costs (Snelling 2008). From the 
patient’s perspective, an important benefit is the convenience that comes with having therapy in the 
home. Baharoon et al. (2011) and Stephens (2013) highlighted that patients who received treatment 
through such programs reported that it is far more convenient than going into hospital. In other words, 
people with chronic health conditions experience benefits from receiving care in their own home. In 
Australia, several hospitals have implemented the hospital at home model of care and refer to it as 
hospital in the home (HITH). Home infusion therapy has been used for multiple treatments such as 
antibiotic infusions, analgesia, hydration, chemotherapy and antineoplastic agents. In a systematic 
review, Shepperd et al. (2009) described HITH as enabling early discharge prevention of re-admission 
from hospital to home to continue medical treatment. In addition, they stated that a variety of patients 
could be treated under the HITH model of care based on their medical condition, including infection, 
post-surgical acute care and infusion therapy. 
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Research problem and study context 
People with RRMS generally have to undergo regular disease-modifying therapies via OITS. Though 
there are many disease-modifying therapies with different benefits, natalizumab is commonly used for 
RRMS (Kappos et al. 2007). Additionally, people with MS who receive natalizumab require admission 
to OITS for at least a one-hour infusion every month. The admission appointment means that people 
often miss work or other activities on the day that they come to hospital to receive infusion therapy 
because of the additional time required in preparation for the appointment. While the majority of 
people with MS receive disease-modifying therapies via OITS, some drugs have a safety profile 
approved for administration in the home care setting. For example, Ducharme, Pelletier and Zacharias 
(2010) confirmed that infliximab therapy is safe to administer in the home setting for people with 
Crohn’s disease.  
 
As a registered nurse who has worked in an acute care hospital, I believe that people with chronic 
illnesses who require regular infusions may want to have a choice of where this treatment is delivered, 
such as in the home environment. In the Australian healthcare system, acute care patients may be able 
to access a ‘hospital in the home’ (HITH) service. This service offers patients the alternative of being 
treated in their own home. However, this service is not yet offered for people with chronic disease 
such as those with RRMS. Therefore, there is a need for a study to gain a deeper understanding and 
overall view of patients’ and healthcare workers’ experiences of the delivery of natalizumab in a home 
setting.  
Aim of the study 
This study is part of a larger project that examined the safety and clinical effectiveness, acceptability 
and cost effectiveness of flexible delivery of natalizumab by ambulatory care nurses for people with 
multiple sclerosis (Schultz et al. 2018). This project has been reported in the Journal of Infusion 
Nursing, in an article titled ‘Developing a model of care for home infusions of natalizumab for people 
with multiple sclerosis’ (see Appendix I).  
 
The aim of this study is to explore and describe the experiences of people diagnosed with RRMS and 
healthcare workers in the transitioning of natalizumab infusions at home. The outcome of this 
qualitative investigation will provide healthcare professionals and policy administrators with the 
groundwork for overcoming obstacles surrounding these patients’ experiences and for improving the 
model of care for treating people with RRMS.  
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Research questions of the study 
This Master of Research by publication involves two stages (in two separate publications) as follows: 
 
• The first stage of this study aims to understand the experiences of people with MS who received 
infusions of natalizumab at home instead of in hospital. This study focused on the research 
question: ‘What are patients’ experiences of natalizumab treatment in a home environment?’ There 
have not been any previous qualitative inquiries into patients’ perspectives on a changed model of 
care from outpatients to the home for the infusion of natalizumab. Studying the qualitative 
evidence may provide a clearer understanding of what it is like for patients to receive natalizumab 
infusions at home. 
• The second stage of this study explored healthcare workers’ experiences of delivering natalizumab 
infusions in a home environment. The study question was: ‘What are healthcare workers’ 
experiences of delivering natalizumab infusions in a home environment?’ 
Significance 
Currently, people with RRMS receive natalizumab intravenous infusions only through OITS. OITS 
administration of natalizumab treatment is becoming a widespread practice alternative to hospital 
inpatient treatment. The treatment cannot be given through an alternative route of administration, such 
as in the form of oral tablets. Natalizumab infusion is one aspect of comprehensive care received by 
people with RRMS; patients are taken care of by special healthcare teams and specific treatment 
programs. The main objective for management of people with RRMS is to give them the highest 
possible quality of life and to enable them to fulfil basic daily activities with no obvious signs of 
physical disability (Miller, Karpinski & Jezewski 2012).  
 
Using the hospital in the home (HITH) model to offer people with RRMS natalizumab infusions in the 
home could be one step forward to achieving this objective. There has been one study conducted at 
the William C. Baird Multiple Sclerosis Centre in Buffalo, New York that used a phenomenological 
methodology to investigate the experiences of individuals diagnosed with RRMS receiving 
natalizumab infusions in clinical settings (Miller, Karpinski & Jezewski 2012). However, no previous 
qualitative research has focused on patients’ experiences of receiving the infusion in their own home.   
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Thesis outline 
The thesis is organised as follows.  
 
Chapter One provides an introduction to the topic under investigation and to the research project. 
 
Chapter Two presents a review of the previous and the current literature, which includes a summary 
of the current state of healthcare services in Australia. 
 
Chapter Three describes the research paradigm, focusing on the exploratory-descriptive study design. 
 
Chapter Four consists of a peer-reviewed article published in the Australian Journal of Advanced 
Nursing, titled ‘Patients’ experiences of natalizumab treatment in a home environment: a qualitative 
study’.  
 
Chapter Five presents an article submitted for publication, under review by the Australian Journal of 
Advanced Nursing, titled ‘Healthcare workers’ experiences of transitioning natalizumab infusions for 
multiple sclerosis patients from hospital services to an in-home setting: a qualitative study’.  
 
Chapter Six provides an overview of the results and discusses the contribution of the thesis to the 
broader literature on a changed model of care from outpatient to the home for the infusion of 
natalizumab.  
Summary of the chapter 
Chapter One introduced the study by outlining some background information about MS and 
natalizumab therapy and placing it within the study context. People with MS come to hospital on a 
monthly basis to receive natalizumab infusions via an outpatient department service. An alternative 
option is to deliver this treatment in a home setting. This chapter set out the aim of the study, namely 
to inform the development of models of care that enable a patient-centred care approach for those who 
are required to participate in long-term care. In addition, the chapter set out the research question and 
the significance of the study. The chapter concluded with the thesis structure. 
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Chapter Two: Literature review 
Chapter Two presents a literature review that was used to set the background for the study and 
publications. The focus of the literature review was to explore the existing research on patients’ 
experiences of infusions within traditional hospital care and in alternative home care. A broad literature 
search was undertaken to identify any gaps in the current research. Prior to conducting the research, a 
preliminary search strategy was used to prepare for the study and to gather information related to the 
research topic. 
Searching the literature  
Searching electronic databases for literature requires an inclusive search strategy to achieve an 
accurate outcome (Whittemore & Knafl 2005). In this study, the search strategy was directed by 
systematic reviews conducted by Shepperd et al. (2016) and Langer-Gould et al. (2006) to ensure that 
new studies were captured. A consultation with a librarian offered an opportunity to review the 
keywords used and to obtain information about each database system, prior to undertaking the search. 
 
In this study two electronic databases, the Medline database and the Cumulative Index to Nursing and 
Allied Health (CINAHL) database, were used in the search for available literature. These databases 
are common databases used in the healthcare field and were an efficient method of identifying studies 
on the index terms used. LoBiondo-Wood and Haber (2006) recommended making use of at least two 
electronic databases to answer a study question. However, other relevant literature was also found 
through websites such as Google Scholar, international institutes (including ProQuest Dissertations), 
and the National Library of Australia  (including Trove). A specific time frame was selected because 
studies into patients’ experiences of infusion therapy in the home commenced in the 1980s and the 
literature from this period is still significant. 
 
Articles had to be available in English for ease of reading and evaluation. As stated above, the search 
started by using keywords from the works by Langer-Gould et al. (2006) and Shepperd et al. (2016), 
to detect relevant literature in the database. The key words used for article 1 were multiple sclerosis, 
model of care, patient-centred, home infusion and hospital infusion. While the key words for article 2 
were model of care, healthcare worker, home infusion, multiple sclerosis and natalizumab. 




The search was conducted during the study period of August 2016 to March 2020. The titles and 
abstracts of all the sourced items were read. Identification of the literature around models of care and 
natalizumab therapy at home commenced with a search of the references cited in the keyword 
literature, reports from organisations such as the Multiple Sclerosis Society of Australia and Infusion 
Nurses Society and commonly referenced studies in the area. In addition, manual searching from the 
reference lists of previous studies was conducted and the search of electronic databases was updated 
frequently, as the study continued. It was identified that no qualitative studies of patient experiences 
of a changed model of care, from hospital to the home, for the infusion of natalizumab had been 
published.  
Review of the literature 
Studies have documented the experiences of people with RRMS in an outpatient service environment 
(Miller, Karpinski & Jezewski 2012). However, they do not state whether patients were offered home 
therapy, or if any patients requested home therapy. Moreover, there has been no study conducted on 
the experience of patients who choose to receive natalizumab infusions outside of the clinical 
environment. The following subsections further explore the literature on OITS and on home infusion 
therapy as an alternative model of care. 
Current model of care: Outpatient intravenous therapy service (OITS) 
OITS requires patients to travel to a hospital for therapy. It provides immediate access to specialists 
and medical equipment when necessary (Tice et al. 2004). The acronym ‘OITS’ is used to denote the 
settings in which intravenous therapy can be delivered without an overnight stay via a hospital 
admission. It therefore includes hospital-based ambulatory care clinics, infusion centres and long-term 
care facilities. In the community, OITS facilities are well-known and accepted methods of providing 
health care. In many countries, the OITS method of administering intravenous therapy outside hospital 
settings has grown rapidly within the healthcare system to deliver a better quality of care (Baharoon 
et al. 2011; Seaton & Nathwani 2000). This practice has been advanced for different reasons, including 
decreasing costs, technological advances in intravenous access and infusion pumps, the friendly 
environment and the accessibility of a skilled service. Moreover, this method of care delivery requires 
a team of healthcare professionals such as doctors, nurses and other staff to coordinate this service. 
 
Intravenous infusion therapy has been delivered in a hospital setting since the 1970s (Alexander et al. 
2011). Outpatient parenteral antimicrobial therapy was focused on delivering care to children 
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diagnosed with cystic fibrosis (Nazarko 2008; Tice et al. 2004). Since then, OITS has also involved 
adult patients diagnosed with medical illnesses, for example cellulitis, to minimise the length of 
hospital stay and the chance of re-admission (Higginson 2011). It was first developed to provide 
parenteral antimicrobial therapy and demonstrated a safe and effective delivery of treatment in an 
alternative setting. There is clear evidence that the management of chronic diseases in an outpatient 
department can promote positive outcomes, including safety, efficacy, cost effectiveness and patient 
satisfaction, as compared to in-hospital care (Alexander et al. 2011). In the United Kingdom, a survey-
based study by Seaton and Nathwani (2000) supported the practice of OITS. They found that it 
provides significant advantages, including enhanced reimbursement and cost management, control, 
efficiency and convenience, and quality control. However, Seaton and Nathwani (2000) highlighted 
that OITS accounts for most of a hospital’s therapy time and revenue but is not for all patient groups 
due to the complexity of their illness management. Following the same thread, Tice et al. (2004) 
supported the idea that the best choice for the model of care such as OITS is dependent on the patient’s 
condition and available resources. 
 
OITS provides care outside the hospital in a client-friendly environment that avoids obstacles such as 
isolation from friends and family and lack of privacy, while providing a wide range of IV therapies 
(Stephens 2013). There are many infusion therapies that can be provided by OITS, which include 
antimicrobials, chemotherapy, parenteral nutrition, IV fluids and monoclonal antibodies. Monoclonal 
antibodies have been developed for the management of people with MS and include natalizumab. 
Currently, intravenous natalizumab is routinely administered via OITS on a monthly basis in sessions 
that last one to two hours. When natalizumab is given in a clinical setting, for example at an OITS, it 
has shown a relatively high safety profile (Van Pesch, Sindic & Fernandez 2016). However, some 
monoclonal antibody therapies, for example infliximab, can be received in alternative settings, such 
as in the community or at home. Ducharme, Pelletier and Zacharias (2010) evaluated the safety of 
infliximab in a community setting and confirmed its safety using a standardised protocol. Therefore, 
it may be possible to provide an alternative setting to OITS, a non-traditional health care model, for 
instance, a home care setting. 
Alternative model of care: Home care service 
Over the past three decades, the use of an alternative model of care has grown worldwide using non-
traditional ‘in-home’ settings. This model has advantages such as minimising the risk of acquiring 
hospital-associated infections and decreasing hospital stays (Snelling 2008). Hospital at home has been 
practised in developed countries, specifically, in the United Kingdom (Kane 2007), Europe (Berntorp 
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& Lethagen 2000), the Middle East (Baharoon et al. 2011), Canada (Moore & Bortolussi 2011) and 
Australia (Montalto 2010). However, despite HITH representing a new hospital system development 
worldwide, there is a significant gap in the literature, and the impact of home care services on clients 
and healthcare professionals has not been explored. 
 
HITH involving infusion therapy has been an effective mode of management of patient illness at home 
since the 1980s (Stephens 2013). The use of home infusion therapy services has grown not only due 
to the development of advances in medical technology in infusion devices but also due to the 
development of new medications. Disease-modifying therapies, which include monoclonal antibodies, 
are part of these developments which can offer more effective, suitable treatment for people with 
chronic disease (Kappos et al. 2004; Stuve 2009). In some countries, such as Canada, certain disease-
modifying therapies are provided to people in their own homes (Ducharme, Pelletier & Zacharias 
2010).  
 
Worldwide, natalizumab infusion is not yet routinely offered for in-home use. By contrast, this practice 
is accepted for other monoclonal antibody agents, such as infliximab therapy, with clear advantages in 
terms of safety, satisfaction and cost. Showing the growing trend to deliver monoclonal antibody 
therapy in a home setting, two studies in Australia have reported the safe delivery of natalizumab 
infusions in the home (Schultz et al. 2019; Vijayan et al. 2017). The delivery model is dependent on 
the patient’s capability and need for medical services (Tice et al. 2004). HITH services, however, 
should be assessed in order to better understand the experiences of people with RRMS to inform the 
development, implementation and monitoring of services provided to such individuals and their family 
members. 
Summary of the chapter 
This chapter outlined that, in recent decades, research into home infusion therapy as an alternative 
model of care has grown. The chapter started by explaining the method of the review of relevant 
literature, through searching the electronic databases Medline and CINAHL. It also presented an 
outline of the current model of care of OITS and the preference for an alternative site for home infusion 
therapy. 
 
The literature review highlighted a gap in the available studies, as no published articles were found 
that focused on patients’ experiences of Tysabri treatment in a home setting. This study may add to 
the current knowledge about how home infusion services benefit patients and may be useful for 
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educating healthcare workers. The next chapter discusses the methodological approach used in this 
study.  
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Chapter Three: Overview of Methodology 
 
The aim of this study is to inform the development of models of care that enable a patient-centred care 
approach for those who require long-term care. Ethics approval was granted by the Royal Adelaide 
Hospital Human Research Ethics Committee (see Appendix 2). As there is limited literature about the 
experiences of patients undergoing infusion in their own home, an exploratory-descriptive qualitative 
study seemed a suitable design to explore the patients’ experiences and to generate a descriptive 
understanding of this phenomenon. The term ‘phenomenon’ was defined by Gerrish, Lathlean and 
Cormack (2015, p. 587) as ‘an occurrence, circumstance, experience or fact that is perceptible to the 
senses’. 
Qualitative research 
Generally, a qualitative research study entails a non-experimental research design that uses data 
description to understand the meaning of a phenomenon. Qualitative research is an interpretative and 
critical approach, because it aims to define a concept and investigate a particular phenomenon of 
interest (Gerrish, Lathlean & Cormack 2015). This is particularly important when conducting a social 
inquiry about individuals’ experiences within their natural setting. Currently, qualitative research is 
used in many different fields, including nursing research. Mason (2002) emphasised that there is no 
common definition of qualitative research; however, the recent definition from a nursing perspective 
by Polit and Beck (2016) suits the purpose of this research. Polit and Beck (2016, p. 741) defined 
qualitative research as ‘the investigation of phenomena, typically in an in-depth and holistic fashion, 
through the collection of rich narrative materials using a flexible research design’. In other words, it 
generates an understanding of an individual’s opinion about their experience, by using a specific 
research design. Therefore, qualitative research offers descriptive information to understand the 
experiences, perceptions and opinions of the research participants.  
 
To gain a deeper understanding and overall view of the patients’ experiences, this study was conducted 
using a qualitative methodology. A qualitative approach allowed the researcher to gain knowledge of 
the phenomenon from the patients’ and healthcare workers’ own perspectives. Qualitative methods, in 
particular interviews and focus groups, were more suitable than quantitative methods for many 
reasons, since the research aim was to gain insight into the experiences of patients having treatment at 
home, rather than in a hospital. Using a specific qualitative research design not only requires an 
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understanding of the nature of the study, but also the type of questions considered to be appropriate. 
As briefly discussed below, there are different research methodologies that could have been employed, 
such as grounded theory, phenomenology and exploratory descriptive.  
Grounded theory study  
A grounded theory study creates a theory about a phenomenon through a systematic process. In 
grounded theory, ‘the investigator develops conceptual categories from the data and then makes new 
observations to develop these categories’ (Bowling & Ebrahim 2005, p. 603). It is designed to focus 
on a process related to an idea and uses this process to create a theory from the opinions of the 
participants. Grounded theory is designed to collect and analyse data from an observational field. As 
the aim of this study was not to develop a new theory, a grounded theory study would not be an 
appropriate design for this research. 
Phenomenology study 
While grounded theory focuses on discovering a new theory through data collection, the intent of a 
phenomenology study is to describe the meaning behind the participants’ lived experiences. The design 
aims to provide detailed information on the meaning of individual daily experiences, but also to 
describe and reflect on them (Gerrish, Lathlean & Cormack 2015). Borbasi and Jackson (2012, p. 257) 
indicated that the purpose of a phenomenology design is ‘to understand and attribute meaning to the 
phenomenon of interest’. As a phenomenology study requires in-depth interviewing with participants 
to understand the deeper meaning of their lived experience, rather than a briefer exploration of the 
patients’ experiences of natalizumab treatment in a home environment, it was not an appropriate 
methodology for this research. The researcher determined that an exploratory-descriptive study design 
was the best method to use when conducting this study. In the next section, exploratory-descriptive 
study design will be discussed in more detail, including references to the literature. 
Exploratory-descriptive study design 
An exploratory-descriptive study design is a common qualitative methodology. It is also classified as 
‘qualitative research with content analysis’, ‘qualitative inquiry’, ‘qualitative research’, or a 
‘qualitative study’ by some researchers (Annells 2007, p. 223). However, the different terms used vary 
depending on the nature of the phenomenon under investigation. Currently, an exploratory-descriptive 
study is the most common approach to qualitative research in the nursing field (Annells 2007; Polit & 
Beck 2016; Schneider et al. 2013).  
 
15 
An exploratory-descriptive study is the exploration of human experiences to either investigate new 
ideas or increase knowledge of a phenomena Reference. Schneider et al. (2013, p. 392) explained this 
design as ‘an “overarching” process whereby researchers do not adopt a traditional philosophical or 
theoretical methodological stance but, instead, use a “free form” approach that adopts general 
principles of qualitative process, such as common data collection and data analysis styles’. There are 
advantages to using this design for this research question. Firstly, it is an ideal design to gather 
individual experiences. Secondly, it is a way of exploring and describing the participants’ experiences 
during the period of study. Finally, it allows the researcher to explore the phenomenon of a change to 
a model of care, and collect descriptive data on patients’ and healthcare workers’ experiences. 
Therefore, this design was considered the most appropriate approach for this study. As stated above, 
the freedom within this design allows for the gathering of data from individuals in face-to-face 
interviews or focus groups, and the use of a thematic method to analyse the data. The specific research 
methods for each phase of the study are outlined in detail in Article One (Chapter Four) and Article 
Two (Chapter 5). The interview questions can be found in Appendix 3. 
Summary of the chapter 
The qualitative research paradigm and philosophical aspects of research designs were briefly explored 
in this chapter. While there are different research approaches, for example grounded theory and 
phenomenology, an exploratory-descriptive design was considered the most appropriate for this study 
to explore the phenomenon of MS patients’ experiences of having natalizumab infusions in their own 
home as an alternative model of care. Also, it will offer knowledge about healthcare workers’ 
experiences in delivering infusions in a home setting. The research design and the rationale for 
choosing this method of enquiry were explained in this chapter. The researcher decided on this 
approach to examine a relatively unstudied field, with limited current information available on the 
subject. The next chapter will present the first published article: ‘Patients’ experiences of natalizumab 
treatment in a home environment: a qualitative study’. 
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Healthcare workers’ experiences of transitioning natalizumab 






This study explored healthcare workers’ experiences of transitioning infusions of 
natalizumab from hospital to a patient-centred model of home care  
 
Background 
Hospital in the home is one of the fastest growing healthcare delivery models. In 
Australia, intravenous infusions are rarely available at home for chronic disease 
patients, such as those with multiple sclerosis. A recent trial of natalizumab infusions 
at home for patients with multiple sclerosis required both the hospital and hospital in 
the home staff to consider the logistics of how this transition could be achieved safely. 
 
Study design and methods 
This was a qualitative study using an exploratory-descriptive approach. Twelve 
participants from two main groups of healthcare workers participated in delivering 
natalizumab infusions during the six-month trial period and were subsequently 
interviewed about their experience. Participants were recruited from a hospital 
ambulatory care day unit and a Home Infusion Team from a private provider of home 
nursing care located in South Australia. The data was analysed thematically.  
 
Results 
Three main themes were identified from the interviews: ‘preparing for change’, 
‘focussing on the patient’, and ‘enhancing professional support and relationships’. 
These findings demonstrated the importance of understanding healthcare workers’ 
experiences of transitioning to a patient-centred model of care, from hospital to home 






Flexibility and good management of logistics is necessary to maintain the standards 
of the health services, which highlights the need for training and professional support 
to facilitate quality home care. This may enhance workers’ sense of professional 
confidence and trust and reduce stress when delivering the home model of care. 
 
Conclusion 
Healthcare workers and patients worked to support one another, not only 
therapeutically but also logistically within collegial relationship and interdependent 
communications. Being flexible, communicating clearly and being willing to work 
together within the team, especially between the hospital in the home staff and the 
hospital staff, was demonstrated to be an important factor for the safe delivery of 
infusions at home. Managing the logistics of delivering a flexible and safe home 
therapy service was an important part of this model of care.  
 
Implications for research, policy, and practice 
The results of this study will be used to inform healthcare teams about the key logistical 
components that are important for healthcare services, when considering transitioning 




Model of care, healthcare worker, home infusion, multiple sclerosis, natalizumab 
 
What is already known about the topic  
• Although outpatient infusion programs are often hospital based, they may be run 
by regional health authorities or private organisations, such as a hospital in the 
home service. 
 
• Healthcare workers delivering a hospital in the home service require advanced 





What this paper adds  
• The development of a comprehensive logistical process, which has the patient at 
the centre of the model of care, enabled natalizumab to be delivered safely in the 
community by healthcare workers.  
 
• Being flexible, communicating clearly and being willing to work together within the 
team, especially between the hospital in the home staff and the hospital staff, was 









Over 25,000 people in Australia have multiple sclerosis (MS), an inflammatory 
disorder of the central nervous system that may result in neurological symptoms and 
increasing disability.1,2 Multiple sclerosis is a chronic neurological disease that 
develops in young adults.1 About three quarters of people with MS are female and the 
majority are diagnosed between the ages of 20 to 40 years.2 Most people with MS 
start out with relapsing-remitting MS (RRMS), which is characterised by relapses or 
exacerbations when symptoms flare up, followed by a variable period of time when no 
symptoms are present, called ‘remission’.3 Currently, the US Food and Drug 
Administration, together with the European Medicines Agency, have approved 13 
drugs for use as RRMS disease-modifying therapies, which help to control the disease 
and improve quality of life.3 Gajofatto and Benedetti emphasised that these therapies 
modulate or suppress the different mechanisms of the autoimmune process that 
underlies the disease, thereby minimising the occurrence of relapse or preventing 
disease progression.4 Natalizumab was one of the first disease-modifying therapies 
approved for the treatment of adults with RRMS in a hospital setting.5,6 
 
Hospital outpatient intravenous therapy services, also known as hospital-based 
infusion centres, are gaining recognition as a beneficial model of care for both health 
services and patients.7 Patients diagnosed with RRMS may require natalizumab 
infusion treatments on an ongoing basis for at least a one-hour infusion every 28 
days.8,9 Natalizumab infusions can be delivered to people with RRMS as an outpatient 
rather than requiring admission to the hospital as an inpatient. While this outpatient 
appointment is a relatively short hospital visit, patients still have to allocate sufficient 
time to travel to and attend the hospital for the treatment and may miss work, study 
and other activities on that day. This is time consuming and inconvenient, not only for 
the patients but also for their family members.10,11 Although outpatient infusion 
programs are often hospital based, they may be run by regional health authorities or 
private organisations. Several studies have recently supported the concept of 
delivering patient care, especially intravenous infusions, away from a hospital and in 
the patients’ home or community environment. This places the patient at the centre of 





Background: ‘Hospital in the home’ model 
Delivering health care for people with chronic health conditions at home is commonly 
known as ‘hospital in the home services’.2 ‘Hospital in the home’ involving infusion 
therapy has been an effective mode of management of some illnesses since the 
1980s.13 The use of home infusion therapy services has grown not only due to the 
development of advances in medical technology for infusion devices but also due to 
the development of new medicines. The development of home infusion treatment 
programs has been influenced by the need to stem the increasing demand for access 
to acute care hospital beds, to decrease the chance of infections and to reduce 
hospital costs.14 Additionally, during the COVID-19 pandemic, the preference for 
people such as those receiving natalizumab for RRMS to avoid the hospital 
environment and self-isolate has increased the need for health managers to rapidly 
consider safer options for delivering ongoing medical treatment. 
 
Disease-modifying therapies are part of a growing group of agents, which includes 
monoclonal antibodies, with the aim of offering more effective, suitable treatment for 
patients with chronic disease.4 In some countries, such as Canada, certain disease-
modifying therapies are provided to people in their own homes.15 For example, 
infliximab therapy, a monoclonal antibody agent used for Crohn’s disease patients has 
a safety profile approved for administration in the home setting. Three studies have 
reported that infliximab therapy for Crohn’s disease is safe to administer in the 
home.15,16 In the United Kingdom (UK), a recent pilot study by Brex et al. on 
natalizumab home infusion reported significantly higher levels of satisfaction (94% to 
100%) after delivering 253 home infusions on 10 highly active MS patients.8 Recent 
studies have piloted home infusions of natalizumab for people with RRMS.9, 17 Despite 
the possibility of adverse events due to natalizumab infusion, these studies stated that 
the participants’ safety was maintained and that participants reported a high level of 
satisfaction. While these three studies documented important findings about the 
patients’ experience of home care, clinicians’ experiences of transitioning to and 
supporting a different model of care have not been studied. Given that healthcare 
professionals are potentially operating in a new environment, and working with a new 
model of care, it is important to understand their perspectives, how they may inform 




only one study conducted in the UK that used a qualitative methodology to investigate 
the experiences of district nurses caring for patients with home chemotherapy.18 The 
authors concluded that the experiences of nurses with home chemotherapy 
highlighted the importance of shared care with patients and learning from colleagues.  
 
This article presents the findings from research which aimed to understand healthcare 
workers’ (HCWs’) experience of transitioning to a patient-centred model of care, from 
in-hospital to at-home, for patients with MS requiring monthly infusions of natalizumab. 




The study was conducted using a qualitative methodology. The study question was: 
‘What are HCWs’ experiences of delivering natalizumab infusions in a home 
environment?’ An exploratory descriptive study design is common among qualitative 
methodologies, also known as ‘naturalistic inquiry’.19(p479) There were advantages to 
using this design for this research question. Firstly, it is an ideal design to gather 
individual experiences during the period of study. Secondly, the researchers sought to 
gain a deeper understanding of the HCWs’ experiences of the model of care used in 
the home environment. The research was approved by the relevant health service 
Hospital Ethics Committee (HREC/16/RAH/192) and all participants provided written 
informed consent before commencing.  
 
Setting and participants 
This study is the qualitative part of a larger study that examined the safety, clinical 
effectiveness, acceptability and cost effectiveness of home infusions of natalizumab 
for people with MS.9 Twelve participants from the two main groups of HCWs delivering 
natalizumab infusions during the six-month study period were interviewed: four from 
the Home Infusion Team (HIT) (a private provider of home nursing care located in 






A total of 110 natalizumab infusions were provided to 36 RRMS patients during the 
six-month period April to September 2017, of which 55 infusions were delivered at 
patients’ homes and another 55 at the ambulatory care day unit.9,20 Semi-structured 
interviews were conducted with the HCWs after the completion of the period of 
delivering natalizumab home infusions. The participants were given a choice between 
participating in a telephone or a face-to-face interview, either individually or as a group. 
The interviews took between 30 and 60 minutes and were digitally recorded. The 
recordings were transcribed and participants were given the option to check the 
transcripts. None of the participants requested to review their transcript.  
 
The transcripts were analysed using Braun and Clarke’s method.21 In this analysis, 
the researchers focussed on the content of the transcripts, then identified  common 
themes. This approach involved grouping concepts, supported by quotations from the 
participants’ interviews.  
 
Issues of reliability and validity  
Reliability and validity are important components in conducting research. In qualitative 
research, validity and reliability are maintained by establishing trustworthiness. 
Trustworthiness can be demonstrated through the process of gathering data.25 For 
this study the same semi-structured questions were used for all participants and two 
researchers independently analysed the transcribed recordings and then came 
together to discuss the findings. In addition, the research team met monthly throughout 
the data collection period. Finally, the researchers maintained an audit trail of the 




The framework that guided the analysis of the data was dictated by the study question. 
Three main themes were identified from the interviews: ‘preparing for change’, 
‘focussing on the patient’, and ‘professional support’. These are presented in Table 1. 




such as H2, at the end of each comment. The HIT HCWs (nurses and courier)are 
identified with the letter H. The ambulatory care day unit HCWs (consultant 
neurologist, neurology nurse consultant, nurse unit managers and nurses) are 
identified with the letter R if they were individually interviewed or the letter F if they 
were interviewed in groups. 
 
Table 1: Outline of themes and subthemes from HCWs’ experiences 
Theme Subtheme 
Preparing for change Comprehensive process of preparation for change 
Extra work in facilitating the change 
Ensuring the cold chain is maintained 
Focussing on the patient Convenience for the patient 
Enhancing professional 
support and relationships 
Training  
Positive collegial relationships 
Nurse–patient relationships 
 
Theme one: Preparing for change 
The importance of establishing a clear process that ensured safe patient care was a 
pervasive theme among the HCWs. This theme has three subthemes: ‘comprehensive 
process of preparation for change’, ‘extra work in facilitating the change’ and ‘ensuring 
the cold chain is maintained’. 
 
Subtheme one: Comprehensive process of preparation for change 
It was clear from the participants’ experiences, across both the hospital and home care 
staff, that there was a lot of consideration during the planning and intervention phase 
of the project, which aimed for accurate documentation and patient safety. Participants 
mentioned that the process was well documented and comprehensive: 
I think for the purpose of the trial, there was a lot more … tracking, 
and you could audit all of that. It was very comprehensive. Probably 
more comprehensive than we would normally do. (F3) 
With regards to the patient recruitment process, participants mentioned a key safety 





So the two safety issues we got around is, one was allergic reaction. 
That’s why we said patients had to have a minimum number of doses 
before they went on the [home] treatment, because then that risk of 
allergic reactions were a lot, lot less. (R2)  
The main concern about transitioning treatment to the home was the management of 
an anaphylactic reaction in a home setting, as the following participant mentioned: 
The only concern I had is that if a patient had a major anaphylactic 
reaction, what was the process that was involved? How was that 
going to be attended? That was my probably single most concern with 
the home infusions. (R1) 
The smoothness of the process of providing natalizumab treatment at home was an 
important part of the experiences of the HIT. The HIT clearly prioritised the patients’ 
perspective, especially the benefits for them of well-organised care. Participants 
stated that they felt more confident and organised as the process developed smoothly: 
But I think from the second time I sort [of] became a little bit more – I 
would get there a little bit early, I felt that my preparation was – making 
them feel comfortable and not being rushed or on a set timeline. I 
think I just became a little bit more organised and relaxed in the 
process. After that I think everything became quite – everything was 
very smooth sailing. (H1) 
As a nurse operating with what we, I have put in place, not any issues 
at all. It was … smooth … So I just thought no, it was good. (H3) 
 
Subtheme two: Extra work in facilitating the change 
Workload management is an approach that is used to ensure a team functions 
efficiently and equitably. Some of the participants emphasised a concern that they had 
at the beginning of the trial process that the transition would generate extra work and 
may have a negative impact on the unit. However, this did not eventuate: 
We had the paperwork … so we knew that those patients had come 




I was concerned about it because of the extra workload that it might 
have – you know, the impact that it might have had on our unit. (F2)  
All of the participants were required to do extra work and planning to ensure that the 
drugs were ordered, ready to be collected and arrived at the correct day and time in 
the patient’s home: 
I think from my point of view, for ordering and things like that, it was a 
lot of work from our side of things, to make sure that the drug was 
available at the times [required]. (F3)  
I was quite clear about when the couriers were coming. We knew 
when they were coming. We had the drug prepared. They came with 
containers that were temperature monitored. We signed for – we 
checked the patients, the dosage, the temperatures, all of that. It was 
really quite thoroughly done; it was very comprehensive. (F3) 
 
Subtheme three: Ensuring the cold chain is maintained 
All of the HIT participants voiced the importance of maintaining the cold-chain process, 
mainly when handling the natalizumab between the hospital (where it was dispensed) 
and the home. The use of a ‘cool pack’ was critical (particularly in the Australian 
summer when the environment is very hot) in maintaining the appropriate temperature 
while the natalizumab was in transit:  
Sometimes we did, now it may be that the nurse had scheduled an 
infusion for 7:00 in the morning, in which case the courier would pick 
up the drug from the hospital the afternoon before that, put it in the 
cold-chain data log and deliver it to the nurse’s home [for appropriate 
ongoing storage]. (H4) 
I really liked the flexibility of it and the fact that I guess the cool pack 
maintained that process. There were a couple of times when the cool 
pack would be delivered to my house, so I would actually have the 




check the temperature control and it was still within its manufacturing 
guidelines so I was happy to do that. (H1) 
Monitoring the temperature within the cool pack provided confidence that the cold 
chain had not been broken: 
What did work really well was the cold-chain hardware and we were 
able to prove that by monitoring not only the in-chain stuff but also the 
longevity of the efficacy, of the cold-chain equipment, which worked 
really well even over two to three days in some cases. (H4) 
During the six-month home infusion trial, a participant reported that only one drug 
dosage was returned to the hospital, because of the patient’s need to change an 
appointment for another week: 
But if it was going to be like a reschedule of a week or more with once 
[only] I think we returned the drug to the hospital. So the beauty of 
that system is that we understood, if you like, the medication issues 
and the cold-chain physics well enough to make those decisions 
appropriately. (H4) 
This analysis highlights participants’ high level of awareness of a key logistical part of 
the process, namely maintaining the cold chain when delivering this service in the 
community. This demonstrates that there can be flexibility while maintaining the 
relevant standard to ensure that the ‘cold chain’ is maintained for the medication. 
 
Theme two: Focussing on the patient 
The focus on delivering a flexible, smooth process to achieve optimum patient-centred 
care was a pervasive theme amongst the participants. A focus on patient-centred care 
was the key philosophy that was adhered to by all of the participants. This theme has 
a sub-theme: ‘convenience for the patient’. 
 
Subtheme one: Convenience for the patient 
Participants discussed how having natalizumab infusions at home provided 




All of them want to know when it’s going to happen permanently. I 
can’t think of one person who didn’t take part in the trial who would 
prefer to come into hospital. It is just so much more convenient for 
them. They all sort of said, look, I think this was fantastic. (R2)  
Everybody really liked it. I think the bulk of the people appreciated the 
opportunity to have it at home, certainly if you've got young children, 
all that sort of thing. (F3)  
In some case infusions at home improved patients’ treatment compliance: 
I could see the benefits, no problems at all. Having the infusion at 
home, I could see there would be better compliance. (R1)  
The participants emphasised that having natalizumab home infusions would free up 
spaces for other patients currently waiting for treatment in the hospital unit: 
We would free up a lot of chairs that – when we try and get patients 
in, it can be very difficult. So you have temporarily given some 
capacity in the bookings. (R1)  
So, we’re growing. We grow about 6 per cent a year, is what I worked 
out some years ago. So, we're not going to get quieter. if there is a 
small population that we can move to community, and it’s a move 
that’s happening nationally as well as internationally. (F3)  
On the other hand, some participants noted that for some patients it was more 
convenient to have the infusion at the hospital: 
The negatives tended to be that if that person worked in town, then it 
might be more convenient for them just to drop into the hospital than 
to have it in their work, or to go back home. (R1)  
All of the HIT interviewees described their approach as ‘very flexible’ in providing 
natalizumab treatment at the patient’s home, as these participants highlighted: 
Yeah, look, I was very flexible. I guess it was always about the – client 
centred and the fact that we had post-op care in the home, that we 




basis … I delivered infusions on public holidays, weekends, I did 
some infusions as late as seven o'clock, seven or eight o'clock at 
night. (H1) 
Flexible delivery of the nursing service was driven by the importance participants 
placed on their patients’ ability to maintain their lifestyle while living with a chronic 
illness: 
Just that it fits into their lifestyle and their – because people have busy 
lives these days so it’s giving them that opportunity to have it done at 
night if they want to ... So it was just – it just made it a lot less 
complicated for the patient. (H2) 
 
Theme three: Enhancing professional support and relationships 
The enhancing professional support and relationships theme included all participants’ 
experiences across both the hospital and the HIT working together throughout the 
project. Professional support included training, establishing clear protocols, ensuring 
the availability of ‘back-up’ if needed and support from all colleagues. Three 
subthemes emerged: training, positive collegial relationships and nurse–patient 
relationships. 
 
Subtheme one: Training 
The HIT nurses were required to attend training to ensure that they had the knowledge 
and skill to carry out the treatment competently in a home setting. This included 
considering the context in which they would practise, as one participant stated: 
I think at the initial orientation with … I think she talked a lot about risk 
assessment. She has done a lot of work with hospital at home and 
infusions in people’s homes. I really asked a lot of questions and 
picked her brains on safety because I guess that is one of the things, 
we do have to be safe in a home when delivering care, another 




The participants also appreciated the importance of observing how the nursing staff 
delivered the treatment in the hospital’s outpatient department, which was a 
requirement for HIT nurses and helped to replicate hospital care in the home 
environment: 
What you do here is done there. It's that reassurance. (F1)  
We had TAPP [Tysabri® Australasian Prescribing Program] training. 
So we were fully aware … to sort of see how the infusion went and 
what you could do when you're actually meeting the patients. So part 
of that meet and greet was also looking at how … to do the infusions. 
(H3) 
 
Subtheme two: Positive collegial relationships  
For the HIT participants to deliver optimal care and maximise the advantages of home 
infusions, it was important for a collaborative relationship to be developed and 
maintained across both services. The participants appreciated the professional 
support from others, such as team members being flexible and working together: 
That was all negotiable and because we were keen to get the process 
or the protocols working smoothly, we were always pleased to 
renegotiate timing and what have you. (H4) 
You just needed to be flexible and work with each other. Which we all 
did as nurses. (H3) 
Some participants mentioned having a ‘back-up’ if they were not able to meet the 
scheduled appointment time with the patient: 
I wanted compliance to treatment to be seen as not driven by the 
nurse. More driven by the patient. Therefore, if there was a patient 
that needed cannulating and be given an infusion, because the other 
nurse couldn't get there, I stepped in. (H3) 
Senior hospital staff were also part of the collegial team and they were approached for 




But yeah, so I would use … staff in [hospital] senior staff. We would 
talk things out. If there was some issues there, we would talk it out 
and we would get a resolution. (H3) 
An HIT  participant acknowledged their responsibility as part of the team to ensure that 
the system worked: 
From that schedule I would make it my duty, if you like, to collect the 
drug at an appropriate time so it could be delivered directly to the 
nurse in the field at the appropriate time. (H4) 
The ability to deliver a good outcome for the patient was at the heart of the willingness 
of all the participants to be flexible in when, where and how care was provided. As a 
team they worked together to ensure that the patients’ needs were central to the 
service being delivered. The patients were also part of the team so the participants 
delivering care in the home were also adaptable to the varying home environments 
while ensuring that standards of care were maintained.  
 
Subtheme three: Nurse–patient relationships 
Some participants emphasised that establishing a therapeutic relationship with the 
patient is necessary not only to resolve any difficulties during the treatment but also to 
make the patients feel comfortable and safe in the care of the visiting nurse. Meeting 
patients in the hospital setting before they transitioned to home care was important to 
promote this relationship: 
It was really good to develop those personal therapeutic relationships. 
I think it was great for them because, they’d met me before, but then 
they’d also continue that follow-up care, so they felt quite safe as well. 
(H1) 
Participants identified that family support was particularly important, not only in their 
presence but also as a part of the patient’s wellbeing, and it contributed to the 
therapeutic relationship:  
Also a few of them had their families around while we were doing the 
infusion, so I’d include them in conversations. That I think helped the 




of the family. It was a very inclusive kind of process because the 
family are a big support to the patient, so they need to be, the family 
need the support as well. (H2) 
 
Discussion 
This exploratory descriptive study recognised the importance of understanding HCWs’ 
experiences of transitioning to a patient-centred model of care, from hospital to home 
infusions of natalizumab. This included their perspectives on the logistics of the 
process and their need for training and support. 
 
Managing the logistics to ensure a flexible, smooth process 
The findings indicated that providing care at the patients’ own home supported the 
principle of patient-centred care due to the flexibility and the convenience provided to 
patients. Offering infusion therapy within a non-hospital environment is common 
practice.22 Organising and managing home infusions requires not only skill in 
delivering the treatment but also in the logistics of maintaining the cold chain, 
particularly when the outside environment may be very hot.23 In this study, managing 
the logistics appropriately was critical to the success of the home-based infusion 
therapy and the administration of the medication. The importance of maintaining the 
safety of the medication and getting it to the patient at the right time and place was 
emphasised by all the participants during the interviews. This required everyone to 
step-up and be accountable for their part in the process and to communicate well with 
each other. 
 
Training and professional support 
Transitioning from hospital to home services requires highly skilled home care 
clinicians. The participants in this study recognised that training and professional 
support are essential when delivering infusions outside a hospital setting. The quality 
of the training and professional support of the HIT affected participants’ experiences 
of delivering infusions in the home setting. In addition, this study revealed that the 




confidence. Depledge and Gracie emphasised that skill-based training with continuing 
education is important to ensure safe treatment is delivered in a non-hospital setting 
such as a home infusion service.24 Consistent with findings from their semi-structured 
study, interviews with nurses delivering home infusions in the United Kingdom found 
that most participants benefitted from the training and education provided, indicating 
that they felt confident and valued the professional support.18   
 
Moving care from the hospital setting to the home setting requires consistent support, 
including enabling the HIT to access the required training and to receive ongoing 
advice from the hospital staff who have the experience and know the patients well. 
However, an international report argued that there is limited professional support for 
clinicians delivering home infusions due to a lack of resources.22, Alexander et al. 
stressed the importance of professional support in ensuring quality of care when 
delivering a home-based model of care.7 Throughout this study, professional and inter-
organisation support were available to the HIT. This involvement provided very 
valuable support to the HIT and enhanced the sense of trust and confidence amongst 
the HIT team and between the HIT and hospital teams.  
 
Managing the change from hospital to home care required good collaboration between 
team. This effective collaboration was vital so that the team could determine the 
logistics of the process of transferring patients who were medically stable to home 
care, how information was communicated across both teams ensuring an audit trail of 
documentation, and then the process of delivering the medication to the patient at the 
time and venue that the patient requested. Even though there was some anxiety at 
the start of the transition, by working together through the concerns raised, all 
participants felt that the patients’ safety was ensured, as much as possible. The 
participants recognised the value of the new service delivery model; though it was 
potentially disruptive to the daily routine in the hospital, it would provide a better quality 
of life for their patients with a long-term chronic disease. It was this central value, 
articulated by all participants, that ensured the new model was about the patient and 
not about the hospital routine. If this value had not been shared across all service 
teams then there would have been many opportunities for the process to be sabotaged 
and the pilot project to fail. The results support the home model of care because of the 




compliance with their treatment.11 In addition, the hospital was able to reduce the 
waiting list for those needing to commence treatment and to provide a more targeted 
service to those who were more acutely ill.  
 
Limitations 
One of the limitations of this study was the relatively small size of the HIT, which 
comprised only three nurses and two couriers. Another is that some of the participants 
were members of the main study’s organising team. Although there is a positive 
perception of home infusions from this six-month study, a longer study period, such 
as a year of home infusions may present issues of sustainability, which indicates that 
further longitudinal studies are warranted. 
 
Conclusions 
This study provides an example of how two teams of health workers can come 
together to work through some difficult logistics of service delivery to establish a better 
way of delivering care that truly puts the patient at the centre. The new model focussed 
on more than the discharge of  patients from one service to another, rather reflecting 
a model of care where patients with a chronic illness transition between home and 
hospital services depending on their wellbeing and the level of medical care required. 
Although HCWs had to accommodate extra work, especially with planning, patient 
assessment, nursing handovers, checking of natalizumab and documentation, they 
felt reassured that people with RRMS will receive a safe natalizumab infusion in an in-
home setting.  
 
Implications for research, policy, and practice 
This study can inform healthcare teams about the key logistical components that are 
important for healthcare services, when considering transitioning to a home-based 
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Chapter Six: Discussion and conclusion 
 
This final chapter discusses and summarises the results of this study. It starts by restating the aims and 
the objectives and provides a summary of the key findings. The chapter then explores the key findings 
from people with MS and healthcare workers’ experiences of infusions at home. The study limitations 
are then explained, along with the implications of the study. 
Restatement of the aims and objectives  
Currently, people with RRMS in South Australia receive intravenous natalizumab infusions only 
through OITS, which is becoming a widespread alternative to inpatient treatment. Offering a home 
therapy service as an alternative model of care for this group of individuals may bring benefits but also 
may create challenges in meeting patients’ needs. As mentioned earlier in this thesis, the aim of this 
study was to inform the development of models of care that enable a patient-centred care approach for 
those who require long-term care. The objectives were to: 
 
• Explore patients’ experiences of natalizumab treatment provided in the home. 
• Explore healthcare workers’ experiences of changing models of care from OITS to transitioning 
natalizumab infusions in a home environment. 
Summary of key findings and discussion 
The findings of this research thesis are presented in two related papers, Chapters Four and Five. Article 
one (Chapter Four) sets out the experiences of people with MS having natalizumab infusions at home. 
A major theme of ‘patient-centredness’ was developed from three categories: ‘in the comfort of their 
own home’, ‘convenience for patients and their families’ and ‘saving time and money’. This is 
supported by international studies, which found that, because of the initial impression of comfort, the 
majority of participants who were given a choice elected to change to in-home infusions (Beijer et al. 
2008; Milligan et al. 2006; Stephens 2013). The majority of participants in the home setting spoke 
about the ‘comfort’ of the home treatment models. The next highlighted category was ‘convenience’ 
for people with MS, with less stress at work or home events, which is very important not only for 
patients but also for their significant others. People with MS specified that providing in-home 
treatment reduced stress. This reflected the findings of Brown et al.’s (2006) study, which found that 
people with MS who reported acute stressors experienced a greater relapse frequency. These particular 
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findings have significant implications for the health and clinical management of chronic disease 
patients, such as those with MS. 
 
Article two (Chapter Five) is a submitted manuscript of healthcare workers’ experience of delivering 
a patient-centred model of care as they change from hospital to home infusion of natalizumab. Three 
themes were identified: ‘preparing for change, ‘focussing on the patient’, and ‘professional support’. 
Healthcare workers were at ease with the process of delivering natalizumab infusion in patients’ own 
home; it was perceived as well-documented, comprehensive and adhering to the cold-chain process. 
Their focus has expanded not only to maintaining quality of care but also to providing support and 
optimal care for both patients and their family. In addition, they recognised that training and 
professional support need to be incorporated into the home-based model of care. The study provided 
further confirmation of existing literature that found that training and education support is vital to 
successful and effective delivery of a home-based model of care (Depledge & Gracie 2006; Turner & 
Pateman 2000). 
 
This thesis has provided an understanding of what it is like to receive and administer infusions in a 
home environment. From the point of view of people with MS, they appreciated and benefited from 
the home infusion provided. This model of care also has benefits for the patients’ family and friends 
because it reduces the burden on them to make transport arrangements. The majority of people with 
MS found that flexibility in negotiating their treatment played a role in enabling them to plan their 
daily activities as they wanted to, rather than have to work around a trip to a hospital. The staff had a 
major focus on delivering a flexible and well-managed process that enabled a home-based model of 
care. The management of the logistics of keeping the cold chain intact and delivering the infusion 
safely required good communication and follow through on designated tasks by all staff across hospital 
and home. It would only take one breakdown in this process to cause a major issue particularly for the 
home care staff. The logistics component is central to the experience of healthcare workers, as it 
encompasses support for most aspects of patient care. Both patients and healthcare workers greatly 
valued the flexibility of delivering natalizumab in-home. This home-based model of care is of 
particular relevance to infusion therapy involving lifelong treatment. The findings from this study may 





The involvement of healthcare workers is an important component in delivering a change in service 
delivery models, because their engagement in the process may influence the patients’ experience of 
receiving infusions in their own home. During the six-month trial, the home infusion team were very 
accommodating about infusion appointments. Patients were allowed to have their natalizumab 
infusions after work hours, or on weekends and public holidays. In addition, the team was also flexible 
about the infusion settings, and one patient was treated at their workplace. Although the trial provided 
flexibility especially with appointment times, this might be challenging to sustain when upscaling to a 
bigger patient cohort and long-term delivery of infusions. For example, providing infusions after hours 
and on public holidays may pose additional costs for the institution which must pay the healthcare 
workers. Another challenge is planning healthcare workers’ catchment area, as some MS patients 
might live far from the work site, causing too much travel time. 
Significance and recommendations 
This study complements the larger study (Appendix 1) in understanding that this is an acceptable 
model of care for the patients and that, with a collaborative, coordinated approach by staff in the 
hospital at home service, it could be undertaken safely. Using the HITH model to offer people with 
MS natalizumab infusions in the home is a step towards hospital services adapting their care delivery 
more towards meeting patients’ needs rather than the convenience of the health service staff. No 
previous qualitative research has focused on patients’ experiences of receiving infusions at home. 
 
It is recommended that the results of this study are used to inform healthcare teams, management and 
policy makers to seriously consider alterations to the models of care for treating RRMS patients. The 
next section will discuss the limitations of the study. 
Research limitations 
The limitations of a study must be taken into consideration when analysing the findings. The following 
are the limitations of this study: 
• The participants in this study consisted of people with MS who were currently receiving infusions 
at a single, metropolitan, tertiary hospital. The outcome may not be generalisable to other groups 
of patients and other people with MS at other hospitals.  
• The interviews were conducted once during the patients’ monthly infusion in the hospital setting 
after they crossed over from home care. There may be some limitations due to the time spent on 
the interview and interruptions, such as infusion pump alarms, that needed nurses’ attention. 
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• Although there is a positive perception of home infusions, longer durations of home infusions may 
alter the findings, which indicates that further longitudinal studies are warranted. 
Conclusion 
This component of a large study has exposed patients’ preferences for home infusion therapy. First, 
the participants revealed that in-home infusion therapy was pleasant, stress free and provided comfort 
within a familiar environment. They identified that these positive experiences provided them greater 
convenience and control over their work and home activities, and most importantly reduced the 
additional fatigue they felt when they had to manage travel to and from the health service and the time 
spent in treatment in a busy hospital environment. In addition, they appreciated the flexibility of 
managing appointments with the in-home infusion team, which benefited their family and themselves. 
Overall, the findings offered support for the delivery of safe infusion therapy in the home. This study 
has demonstrated that, with a carefully considered clinical process, patient-centred care can become a 
reality for patients with MS. It does require healthcare staff to be supported in changing the way they 
work, but if they truly believe in their patients being at the centre of the care, are in the environment 
they want to be in, then change must occur.   
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M
ultiple sclerosis (MS) is a chronic autoimmune 
disorder causing inflammation, demyelination, 
and degeneration of the central nervous system 
and affecting some 2 million people worldwide.1 
Natalizumab is a disease-modifying therapy that reduc-
es the relapse rate, number of lesions, and progression 
of disability for people with relapsing-remitting MS.2 A 
monoclonal antibody, natalizumab is delivered as a 1-hour 
intravenous (IV) infusion of 300 mg every 28 days.3 It is 
generally well tolerated by patients through peripheral 
IV administration, although adverse drug events include 
hypersensitivity reactions (eg, anaphylaxis), infections (eg, 
urinary tract infection), and less serious infusion-related 
reactions occurring during or up to 1 hour after the infu-
sion (eg, fatigue and headache).4 Acute hypersensitivity 
reactions (eg, urticaria) occur in 3% to 4% of patients, with 
serious hypersensitivity anaphylaxis reactions occurring in 
1% of patients.2,5 Infusion-related reactions are typically 
nonspecific and, in addition to fatigue and nausea, may also 
include weakness, dizziness, sweating, fever, rash, rigors, 
diaphoresis, slow pulse, and/or a moderate drop in blood 
pressure, dyspnea, chest pain, and leg bruising.3,6,7
The safety of natalizumab in the long term is consistent 
with shorter-use safety profiles.8,9 For long-term use the 
most significant safety concern with natalizumab is pro-
gressive multifocal leukoencephalopathy (PML). PML is an 
opportunistic central nervous system infection that has 
been associated with John Cunningham virus.10 First identi-
fied in 2005,11,12 the incidence of PML in patients who had 
received natalizumab is 4.2 cases per 1000.12,13 Anti-John 
Cunningham virus antibody index testing, regular magnet-
ic resonance imaging monitoring, and testing for clinical 
manifestations are recommended to reduce the risk of PML 
from natalizumab.10,12,14
Natalizumab infusions are conventionally delivered in 
hospitals, physicians’ offices, MS clinics with infusion cen-
ters, and free-standing infusion centers with physician 
supervision.15 In South Australia, patients receive natal-
izumab infusions in hospital-based outpatient clinics.16 
However, for people with chronic disease, home care can 
lead to better outcomes through avoidance of travel times 
and out-of-pocket expenses.17,18 This reflects a growing 
trend worldwide toward delivery of health care in the home 
rather than hospital.19,20
Home care is defined as “the care provided by profes-
sionals to people in their own homes with the ultimate goal 
of not only contributing to their life quality and functional 
health status, but also to replace hospital care with care 
in the home for societal reasons.”21(p861) In parallel to the 
broader provision of health care at home, home infusion 
therapy is the administration of medications using IV, 
subcutaneous, and/or epidural routes in the home set-
ting.22 Beginning with home parenteral nutrition in the late 
1970s23 and home IV immunoglobulin therapy,24 the move 
to home infusions has extended into a range of diseases 
and treatments. For example, home-based chemotherapy 
has recently been shown to be feasible, safe, and valued as 
an alternative to treatment at an outpatient clinic.25
There has been little progress in delivering monoclonal 
antibody treatments at home, although home infusions of 
infliximab for people with Crohn’s disease was trialed for 29 
adults in the Netherlands26 and 10 children in the United 
States.27 Similarly, the first at-home natalizumab infusion 
service in which 34 patients received nearly 500 doses 
in total at home was recently described in a conference 
abstract.28 No specific details were published about the 
protocol for home infusions or how it was developed and 
approved.
Providing patients with choice and flexibility about 
where they are able to receive their treatment and who 
can provide it is a central tenet of patient-centered care.29,30 
To support the provision of patient-centered care and 
provide home care as a safe option to people with MS, it 
is necessary to develop a new model of care. A model of 
care is defined as “an overarching design for the provision 
of a particular type of health care service that is shaped by 
a theoretical basis, evidence-based practice and defined 
standards.”31(p47) The aim of this study was to develop a 
patient-centered MOC for home infusions of natalizumab 
for people with MS.
METHODS
The concept of home infusion therapy was applied to peo-
ple receiving natalizumab for MS. The research team drew 
on extant literature and evidence-based practice, clinical 
and research experience, and existing standards and poli-
cies to develop a patient-centered MOC.
Definitions and Framework for the New MOC
To guide the new MOC, the Institute of Medicine’s defi-
nition of patient-centered care was used: “Providing care 
that is respectful of, and responsive to, individual patient 
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preferences, needs and values, and ensuring that patient 
values guide all clinical decisions.”30(p6) This definition pro-
vided the foundation for many of the dimensions of the 
MOC, which naturally placed patients at its center and 
incorporated 8 key components of patient-centered care: 
(1) respect for patients’ preferences and values, (2) emo-
tional support, (3) physical comfort, (4) information, com-
munication, and education, (5) continuity and transition, 
(6) coordination of care, (7) the involvement of family and 
friends, and (8) access to care.29
This study was guided by the United Kingdom Medical 
Research Council framework for developing and evaluating 
complex interventions.32 A search for relevant evidence 
(“preclinical or theoretical phase”) was first conducted in 
March 2016 and updated in June 2018. PubMed, Scopus, 
Cochrane Library, Joanna Briggs Institute, and Cumulative 
Index to Nursing and Allied Health Literature databases 
were searched using search terms and medical subject 
headings including “home infusion”; “home care”; “natal-
izumab”; “monoclonal antibody”; “adverse events”; “IV 
infusion”; “multiple sclerosis”; and “home care services.” 
The search identified 35 published studies relevant to the 
aims of this study, including studies in 5 main topics: safety 
and adverse effects of natalizumab,2,4-13 home care,19-22,33-36 
home infusions,18,24-28,37-41  infusion guidelines and stan-
dards,15,42 and medication management.43 In addition to 
relevant published studies, product information,3 training 
guides,44 Australian health care standards,45 and organiza-
tional protocols16 were included, and US infusion therapy 
standards46 were reviewed for applicability in the Australian 
setting. Critical appraisal of studies was not conducted.
Key findings from the included studies were extracted 
and discussed during regular (4–6 weekly) research team 
meetings in 2016–2017. The discussions focused on the 5 
main topic areas and involved all members of the research 
team, representing home care nursing, nurse education 
and regulation, day unit clinicians, health policy and eco-
nomics, neurology, pharmaceutical industry, evidence syn-
thesis, and patient safety research. In phase 1 modeling, 
which involved modeling to improve understanding of the 
components of an intervention,32 the components of the 
MOC to safely deliver home infusions of natalizumab were 
developed inductively from the literature and research 
discussions. Decisions were made by consensus during 
meetings, and draft minutes were circulated for discussion 
and confirmation at subsequent meetings.
The resulting MOC was to be used to design a phase 2 
exploratory trial,32 testing the feasibility of delivering home 
infusions and providing preliminary data about safety and 
effectiveness.47 As the MOC was designed to be formally 
evaluated, it included components related to data collec-
tion and documentation of adverse events.
Setting
The study was set in Adelaide, South Australia, as a collab-
oration among a university, a major public metropolitan 
acute care hospital, a private provider of home nursing, 
and a pharmaceutical company. Meetings occurred at the 
day-infusion service within the hospital outpatient area. 
The MOC was intended to replicate care provided in the 
day-infusion service; therefore, other hospital medical and 
nursing staff were also consulted, and the perspectives of 
patients with MS were gained opportunistically by staff 
delivering infusions in the hospital clinic.
Ethics
As the development of the model of care involved review 
of literature, policy and current practice, and discussions by 
researchers, formal ethical approval was not required for 
phase 1 modeling. The phase 2 study protocol, based on 
the MOC developed here, was subsequently reviewed and 
approved by the Royal Adelaide Hospital Human Research 
Ethics Committee (HREC/16/RAH/192).
RESULTS
The new MOC developed for home infusions of natalizum-
ab is summarized in Figure 1. The MOC was composed 
of 9 dimensions, in addition to the central concept of 
patient-centered care at home for people with MS. Each 
dimension is described in more detail in the Figure.
Home Nursing Care Provider
The hospital does not provide a home nursing service; 
therefore, a private provider of home nursing care (Post-
Op Care at Home Pty Ltd [POCaH]48) was contracted to 
deliver the home infusions. Three registered nurses, each 
with more than 10 years of experience, were employed 
to deliver infusions. Appropriate insurance coverage (ie, 
professional indemnity, public liability, and work injury) 
was in place. Equipment used by the home nursing provid-
er included an infusion stand, consumables, and vital signs 
monitoring (temperature, blood pressure, and respiration). 
The home care provider was represented on the research 
team and led much of the developmental work required to 
operationalize the model of care. The hospital lacked fund-
ing for home nursing; therefore, the home nursing care and 
consumables were funded by Biogen Australia and New 
Zealand, manufacturers of natalizumab.
Competency of Nurses
Clinical competency is essential to maintaining patient safe-
ty; for infusion nursing, such competencies include clinical 
management of special populations, anatomy and physiol-
ogy, safety considerations, vascular access device planning, 
and management and infusion administration.46 Sound 
patient assessment, documentation, and patient education 
skills are essential for home infusion nursing as well.37
The registered nurses delivering home care were 
required to undertake the following: (1) a half-day orienta-
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of any adverse events, and training of home care nurses. 
The new MOC is responsive to patients’ needs and prior-
itizes the nurse–patient therapeutic relationship through 
mutual respect, acknowledgment of autonomism, and 
sharing goals.50 The MOC helps to meet Multiple Sclerosis 
Australia’s position statement on Health and Community 
Services: “People with MS should have access to a range 
of coordinated and integrated health and community care 
services, in line with their needs.”51(p1)
The proposed new MOC has 9 dimensions in addi-
tion to a central component of patient-centered care at 
home. Most of these map to the 4 key areas identified as 
predictors of positive outcomes in infusion nursing42: (1) 
appropriate patient selection: patient safety and managing 
adverse events; (2) effective patient education: handing 
over patients; (3) meticulous patient care and comprehen-
sive assessment and monitoring: home nursing providers, 
competency of nurses, compliance with standards, and 
documentation and data collection; and (4) interprofes-
sional communication and collaboration: patients from 
the hospital clinic and medical courier. The one other 
dimension of the MOC is safe environment, which seeks 
to manage risks from the home environment to both staff 
and patients.
The planning for the new MOC has ensured that the pre-
conditions for implementation and evaluation are in place 
before the commencement of the evaluation.31 A recent 
phase 2 pilot study evaluated the safety, feasibility, accept-
ability, clinical effectiveness, and costs of the new MOC.52 
Patient perspectives of the MOC have also been collected to 
inform its potential further development.53 Future consid-
erations of scale up and sustainability of the home infusion 
MOC should be informed by the phase 2 trial52 and future 
phase 3 and phase 4 studies.32 Sustainability of funding 
home nursing is clearly paramount to greater uptake across 
the Australian health system. Although cost savings are 
consistently reported for home infusions across a range of 
therapy indications,40 operationalizing funding between dif-
ferent parts of the health system is likely to be challenging.
Patient Centeredness in Home Infusions
The philosophy and practice of patient-centered care should 
be at the core of the new model of care.54 Patient-centered 
care values the needs of patients, caregivers, and staff and 
emphasizes the reciprocity of therapeutic relationships and 
responsiveness to individual patient’s needs, values, and 
preferences.29,30 Respect; coordination and integration of 
care; information, communication, and education; physical 
comfort; emotional support; and involvement of family and 
friends are all key dimensions to patient-centered care.55 
In the new MOC for home infusions, these dimensions are 
apparent through the greater flexibility and patient involve-
ment in the delivery of care and the timing and location for 
infusions; for example, infusions can be given after hours, in 
the patient’s home or that of a friend or family member, or 
in the patient’s workplace. The model of care also permits 
greater flexibility in rescheduling infusions. These practical 
examples of patient-centered care can help to embed it into 
home infusion clinical practice.
Patient Safety and Quality of Care
Maintaining patient safety and preventing complications in 
the context of delivery of care at home are paramount.42 
Homes lack specialized equipment available in acute care 
settings, and care at home may be less structured and less 
regulated.33 Patient safety was addressed by restricting 
patient eligibility to those who had previously received at 
least 6 natalizumab infusions and were deemed stable by 
neurologists, developing clear guidance for home nurses 
to manage an adverse event, replicating the care provided 
in the clinic setting using appropriate standards of care 
and ensuring the competency of the home care nurses. It 
is expected that these measures will ensure the safety of 
patients with MS at home, although further evaluation of 
the MOC is likely to be required.52
This proposed model of care reflects other home care 
initiatives designed to improve efficiency, patient cen-
teredness, safety, and quality, while reducing health care 
costs and meeting greater demand.21 Treatments that have 
recently been shown to be safe and efficacious when deliv-
ered at home include IV antibiotics for cellulitis,41 enzyme 
replacement therapy for Gaucher disease56 and Fabry 
disease,17 and complex chemotherapy in acute leukemia 
and lymphoma.38 Possible benefits from home care include 
improved adherence to treatment, better quality of life and 
clinical outcomes, reduced health system costs, and greater 
convenience to patients.17,18
LIMITATIONS
The study is limited to a single medication, although it is 
probable that key learnings can be adapted to other infu-
sion medications and for other types of chronic diseases. 
Although the team conducted a comprehensive search for 
literature across multiple databases, it is possible that rel-
evant articles were not included in our search results. Care 
protocols from only 1 organization were used as the basis 
for care in the day-infusion clinic.
CONCLUSION
The new MOC has been developed to allow people with MS 
to receive infusions of natalizumab at home and addresses 
9 key dimensions of patient centeredness. The MOC pro-
vides practical examples of patient-centered care to guide 
clinical practice for this patient population in the home set-
ting. The need to ensure patient safety in the home setting 
is integral to the new MOC. Additional work is required to 
evaluate the model of care and scale it up to ensure its util-
ity at the health system level across multiple hospital sites.
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Appendix 3: Interview questions 
 
Patient interview questions 
 
1. Can you tell me about your experiences of receiving natalizumab infusions at your 
own home? 
 
2. What words would you use to describe your experiences? 
 
3. What impact did the setting for receiving infusions have on your own and your 
families’/partners’ routine?  
 
4. What is most important to you as a patient when receiving your infusion?  
 
o How does receiving treatment at home compare to receiving it at the 
ambulatory day care unit? 
 
o Do you have a preference for receiving the treatment at home or at the 
ambulatory day care unit? If so, can you explain why? 
 




Health care workers’ (Home Infusion Team) interview questions 
 
1. Could you please share with us how you have started working with the Home 
Infusion Team? 
- How did you know about the project? 
 
2. What training have you received as a preparation for this project? 
- Did you feel prepared for the project? 
 
3. How did you feel when you learned you were going to deliver natalizumab infusions 
at patients’ homes? 
 
4. Reality VS expectations 
- Did you learn everything beforehand or did you have to learn on the job? 
- How would you describe the experience? 
 
5. What do you perceive to be your main task in meeting with the patient and family? 
- What is your view of the patient and family presence in the care scenario? 
- Were there challenges? 
- How would you describe the therapeutic relationship with home care patients as 
part of the trial? 
o Pre-interview 
o During infusion 
o Post infusion 
- Family members involvement 
o Where the family members present? 
o If present, what sorts of interaction did they have? 
 
6. What does ‘flexible’ mean for you as a nurse, in terms of how home infusions are 
provided? 
- Nurses’ perspective on taking patient preference into consideration 
- Also, the need to reschedule for patient’s health issues 
- Exploring meeting and infusion times (nurses and patients’ preference and needs) 
 
7. Nurses’ perceived need for support from the Home Infusion Team 
- In terms of safety, what support do you need when delivering natalizumab? 
- Who will you get support from? 
 
8. Have you incurred out of pocket expenses? 
- Petrol 
- Car km 
- Car’s wear and tear 
- Parking ticket 
 
9. Patient safety 
- Adverse event 
o What are your thoughts on the documents sent out to record side effects 
from infusion? 
o Do you have any concerns about the possibility of an adverse event? 
 
